Log in to save to my catalogue

Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated wi...

Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated wi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b7ca166b3bb24b038b8aa6431c3ba065

Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

About this item

Full title

Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

Publisher

London: BioMed Central Ltd

Journal title

Acta neuropathologica communications, 2023-09, Vol.11 (1), p.1-153, Article 153

Language

English

Formats

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

Background One of the most significant challenges in patients with medulloblastoma is reducing the dose of craniospinal irradiation (CSI) to minimize neurological sequelae in survivors. Molecular characterization of patients receiving lower than standard dose of CSI therapy is important to facilitate further reduction of treatment burden. Methods W...

Alternative Titles

Full title

Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b7ca166b3bb24b038b8aa6431c3ba065

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b7ca166b3bb24b038b8aa6431c3ba065

Other Identifiers

ISSN

2051-5960

E-ISSN

2051-5960

DOI

10.1186/s40478-023-01652-4

How to access this item